Gen9, SynbiCITE Announce Partnership
News Feb 18, 2016
Gen9, a leader in the development of scalable technologies for synthesizing and assembling DNA, and SynbiCITE, a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting adoption and usage of synthetic biology, today announced a partnership that provides members of the SynbiCITE research community access to Gen9’s high-throughput BioFab® platform for gene synthesis.
“Synthetic biology has been named one of the eight great British technologies of the future. It has enormous potential to advance the research of our members who are working on many societal challenges, from pollution to hunger to disease,” said John Collins, Ph.D., Commercial Director at SynbiCITE. “Gen9’s DNA synthesis technologies will be an invaluable resource to our members. These types of industry partnerships enable faster commercialization of breakthrough technologies in the space.”
Since 2013, SynbiCITE has been fostering innovation and collaboration with a goal of accelerating the commercialization of synthetic biology products, tools and processes. Members receive access to education, funding opportunities, laboratory facilities and the latest synthetic biology technologies. SynbiCITE is funded by the UK Research Councils, Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council (BBSRC), Innovate UK, and its industrial and academic partners.
Central to the Gen9 and SynbiCITE collaboration is Gen9’s BioFab® platform for manufacture of high-quality, low-cost synthetic DNA at unprecedented scale and accuracy. With access to this technology, scientists can design more powerful experiments and test many hypotheses simultaneously, resulting in faster and more effective research outcomes.
“Our mission is to empower scientists through the limitless possibilities of synthetic biology,” said Kevin Munnelly, President and CEO of Gen9. “We are excited to collaborate with SynbiCITE, a visionary organization that shares our goal of making synthetic biology accessible to all researchers. We look forward to the cutting-edge advancements that will be realized through our partnership.”
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.